铂类耐药的非小细胞肺癌的治疗策略  

Treatment Strategy of Platinum-resistant Non-small Cell Lung Cancer

作　　者：何玲[1] 郭成龙 王兰[3] HE Ling;GUO Chenglong;WANG Lan(Gansu University of Chinese Medicine,Gansu Lanzhou 730000,China;Affiliated Hospital of Gansu University of Chinese Medicine,Gansu Lanzhou 730000,China;Gansu Tumor Hospital,Gansu Lanzhou 730050,China)

机构地区：[1]甘肃中医药大学,甘肃兰州730000 [2]甘肃中医药大学附属医院,甘肃兰州730000 [3]甘肃省肿瘤医院,甘肃兰州730050

出　　处：《中国医药导刊》2018年第8期472-476,共5页Chinese Journal of Medicinal Guide

基　　金：甘肃省自然科学基金项目(项目编号:1606RJZA148;项目名称:STAT3信号通路的异常激活与肺癌A549/DDP细胞耐药的相关性研究)

摘　　要：铂类化疗药物自问世以来是多种肿瘤治疗方案中必不可少的组成部分。在非小细胞肺癌(NSCLC)治疗中,以铂类为基础的化疗方案发挥着举足轻重的作用。随着病情进展,肿瘤细胞对化疗药物产生耐药,影响患者疗效和预后。分子基因检测技术的迅猛发展,为铂类耐药后的治疗提供了更多选择。本文旨在为NSCLC患者铂类耐药后的治疗提供一些思路。Platinum-based chemotherapeutic drugs have been an essential component of many cancer treatment programs since their introduction. Platinum-based chemotherapy regimens play an important role in non-small cell lung cancer（NSCLC） treatment. As the disease progresses, tumor cells become resistant to chemotherapeutic drugs, which affects patients＇curative effect and prognosis. The rapid development of molecular gene detection technology has provided more options for the treatment of platinum-based drug resistance. This paper aims to provide some ideas for the treatment of NSCLC patients with platinum-based drug resistance.

关 键 词：肺癌 铂类药物 耐药机制 靶向治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]